Sikkim Journal

Advanced Pancreatic Cancer Market to Grow at a Substantial Growth Rate by 2032 – DelveInsight | Key Companies – FibroGen, SynCore, AB Science, Silenseed, AstraZeneca, Pfizer, NanOlogy, and Others

 Breaking News
  • No posts were found

Advanced Pancreatic Cancer Market to Grow at a Substantial Growth Rate by 2032 – DelveInsight | Key Companies – FibroGen, SynCore, AB Science, Silenseed, AstraZeneca, Pfizer, NanOlogy, and Others

April 18
22:44 2022
Advanced Pancreatic Cancer Market to Grow at a Substantial Growth Rate by 2032 -  DelveInsight | Key Companies - FibroGen, SynCore, AB Science, Silenseed, AstraZeneca, Pfizer, NanOlogy, and Others
Delveinsight Business Research LLP
DelveInsight’s “Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Advanced Pancreatic Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Advanced Pancreatic Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Advanced Pancreatic Cancer Market

Advanced Pancreatic Cancer: An Overview

Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States in the near future. In the US, pancreatic cancer is the 9th or 10th most commonly diagnosed cancer (depending on gender). A clinical/radiographic stage classification for pancreatic cancer suggests a three-stage classification (potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings.

Advanced Pancreatic Cancer Market Key Facts

  • As per an article published by Osipov et al. titled, “Locally Advanced Pancreatic Cancer”, considering the lack of screening options and the ambiguity of symptomatology, roughly four out of five patients with pancreatic cancer are diagnosed as having a locally advanced or metastatic disease that is initially not amenable to surgery.

  • According to the National Cancer Registration and Analysis Service, there were 53,265 patients diagnosed with pancreatic cancer in England between 1998 and 2006. Around 411 patients were aged between 20 and 39, which equated to an average of 23 cases per year. There were less than 50 cases per year for those in their 30s and an average of 185 per year for those in their 40s.


Advanced Pancreatic Cancer Market

Advanced Pancreatic Cancer market size is expected to increase during the forecast period owing to the rise in the number of incident cases in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Advanced Pancreatic Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Advanced Pancreatic Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Advanced Pancreatic Cancer Epidemiology

The epidemiology section covers insights into the historical and current Advanced Pancreatic Cancer patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Advanced Pancreatic Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Advanced Pancreatic Cancer market or expected to get launched in the market during the study period. The analysis covers Advanced Pancreatic Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Advanced Pancreatic Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in various stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Advanced Pancreatic Cancer Therapeutics Analysis

Apart from the already existing players, there are several emerging key players, which are expected to change the dynamics of the locally advanced or metastatic pancreatic cancer market in the coming years owing to the positive outcomes of the emerging pipeline candidates.

Some of the key companies in the Advanced Pancreatic Cancer Market include:

  • Eli Lily

  • FibroGen 

  • SynCore Biotechnology 

  • AB Science 

  • Silenseed

  • AstraZeneca 

  • Pfizer 

  • NanOlogy 

  • NantKwest

  • ImmunityBio 

  • PharmaCyte Biotech 

  • Rafael Pharmaceuticals 

  • Galera Therapeutics 

  • OSI Pharmaceuticals 

And many others.

Advanced Pancreatic Cancer Therapies Covered in the report include:

  • NanoPac

  • CPI-613

  • GC4419

  • Cell-in-a-Box

  • Avelumab

  • AZD6738

  • Masitinib

  • EndoTAG-1

  • KRAS (siG12D) LODER

  • Pamrevlumab (Anti CTGF antibody)

  • PD-L1 t-hank and N-803

  • Tarceva (erlotinib)

  • Gemzar (gemcitabine)

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Advanced Pancreatic Cancer Competitive Intelligence Analysis

4. Advanced Pancreatic Cancer Market Overview at a Glance

5. Advanced Pancreatic Cancer Disease Background and Overview

6. Advanced Pancreatic Cancer Patient Journey

7. Advanced Pancreatic Cancer Epidemiology and Patient Population

8. Advanced Pancreatic Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Advanced Pancreatic Cancer Unmet Needs

10. Key Endpoints of Advanced Pancreatic Cancer Treatment

11. Advanced Pancreatic Cancer Marketed Products

12. Advanced Pancreatic Cancer Emerging Therapies

13. Advanced Pancreatic Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Advanced Pancreatic Cancer Market Outlook (7 major markets)

16. Advanced Pancreatic Cancer Access and Reimbursement Overview

17. KOL Views on the Advanced Pancreatic Cancer Market.

18. Advanced Pancreatic Cancer Market Drivers

19. Advanced Pancreatic Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Decompensated Cirrhosis Market

DelveInsight’s “Decompensated Cirrhosis Market” report delivers an in-depth understanding of the Decompensated Cirrhosis, historical and forecasted epidemiology as well as the Decompensated Cirrhosis market size, share, and trends in the 7MM.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles